Mesothelioma News and Research

RSS

Mesothelioma is a form of cancer that is almost always caused by previous exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or have been exposed to high levels of asbestos fibers.

Malignant mesothelioma diagnosis with an E-nose: an interview with Associate Professor Deborah Yates, UNSW

Malignant mesothelioma is a rare tumor of the pleura which is the lining of the inside of the chest wall. It is highly linked with asbestos exposure.

16 Aug 2012

Verastem second quarter net loss increases to $6.8 million

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today reported financial results for the quarter ended June 30, 2012, and also commented on certain corporate accomplishments and plans.

13 Aug 2012

New research center to expedite study of gene transfer approach

In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

6 Aug 2012

Novartis, Penn partner to study and commercialize novel cellular immunotherapies for cancer

6 Aug 2012

E-nose detects malignant mesothelioma

Australian researchers have developed a breath test using an electronic nose to help diagnose malignant mesothelioma in its early stages, a potentially life-saving move.

31 Jul 2012

NCCN Guidelines for Patients: Lung Cancer Screening now available free of charge

The National Comprehensive Cancer Network (NCCN), with the support of the NCCN Foundation and Lung Cancer Alliance, announces the latest addition to the library of NCCN Guidelines for Patients, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

19 Jul 2012

IASLC to host 5th Latin American Conference on Lung Cancer in Brazil

The International Association for the Study of Lung Cancer (IASLC) is hosting the 5th Latin American Conference on Lung Cancer July 25 to 27 in Rio de Janeiro, Brazil. Nearly 1,000 medical professionals will gather to discuss the latest lung cancer research and treatment.

23 Jun 2012

Scientists discover one of the most important cellular mechanisms behind meningioma

Johns Hopkins researchers say they have discovered one of the most important cellular mechanisms driving the growth and progression of meningioma, the most common form of brain and spinal cord tumor. A report on the discovery, published in the journal Molecular Cancer Research, could lead the way to the discovery of better drugs to attack these crippling tumors, the scientists say.

14 Jun 2012

Researchers find pathway for origin and growth of the most common form of brain and spinal cord tumor – meningioma

Johns Hopkins researchers say they have discovered one of the most important cellular mechanisms driving the growth and progression of meningioma, the most common form of brain and spinal cord tumor.

12 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Study provides novel mechanism of action of anti-cancer compound: perifosine

Aeterna Zentaris Inc. today announced that an article published in the May 2012 issue of Plos One, outlines a novel mechanism of action of the Company's oral anti-cancer compound, perifosine, which could provide a rationale for a novel approach to the treatment of Malignant Pleural Mesothelioma (MMe), an aggressive type of cancer associated with exposure to asbestos.

2 Jun 2012

FDA decides to strengthen warning labels on oral contraceptive YAZ, Yasmin

The Federal Drug Administration (FDA) has recently decided to strengthen warning labels on the oral contraceptive YAZ and its sister drug Yasmin regarding increased risks of blood clots from using the medications.

17 May 2012

Developments in mesothelioma treatment presented at 3rd European Lung Cancer Conference

New results presented at 3rd European Lung Cancer Conference in Geneva, Switzerland show important steps being made to improve the diagnosis and treatment of malignant pleural mesothelioma, an aggressive cancer of the outer lining of the lungs caused by asbestos exposure.

19 Apr 2012

Patients with early stage MPM may be eligible for aggressive multi-modality therapy

Patients with early stage malignant pleural mesothelioma (MPM), a cancer that develops in the lining of the lungs, may be eligible for aggressive multi-modality therapy involving surgery, radiotherapy and chemotherapy.

16 Mar 2012

Springer adds 6 new quarterly clinical review journals to medicine portfolio

Springer is adding six new quarterly clinical review journals to its existing medicine portfolio in March 2012. These new journals will expand the publisher's medical specialty coverage, focusing on dermatology, geriatrics/gerontology, nutrition, obesity, obstetrics/gynecology and respiratory care.

29 Feb 2012

Baron and Budd now offers free wristbands to help raise awareness of mesothelioma

The national mesothelioma law firm of Baron and Budd is now offering free wristbands to help raise awareness of mesothelioma cancer. The wristbands are available here and come in adult and children's sizes.

23 Feb 2012

Two new NCCN guidelines for patients with colon and prostrate cancer

In order to provide people with cancer and their caregivers state-of-the-art treatment information in patient-friendly language, the National Comprehensive Cancer Network (NCCN) has developed two new publications: a new release of the NCCN Guidelines for Patients: Colon Cancer and an update to the NCCN Guidelines for Patients: Prostate Cancer.

9 Feb 2012

Clinical Cancer Research publishes results of Aduro's ANZ-100 and CRS-207 Phase 1 studies

Aduro BioTech, Inc. is pleased to announce the publication of two therapeutic cancer vaccine Phase 1 studies in Clinical Cancer Research. In the article, which was featured as one of the highlights of the issue, Dr. Dung Le et al. reported that intravenous administration of ANZ-100 and CRS-207 was well tolerated in subjects with advanced, treatment-refractory cancers.

7 Feb 2012

UHCMC now offers HITEC for women with gynecologic cancers

Patients with gynecologic cancer have new hope in a novel technology now offered at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center. A team of cancer specialists, led by Robert DeBernardo, MD, is among the first in the nation to launch a dedicated program using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat ovarian, endometrial and select other cancers.

21 Jan 2012

PMC receives $100,000 donation for new mesothelioma research laboratory

Pacific Meso Center (PMC) at the Pacific Heart, Lung & Blood Institute (PHLBI) announces a generous donation of $100,000 from Roger and Ann Worthington.

26 Dec 2011